We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CARM market cap is 19.4M. The company's latest EPS is USD -2.0809 and P/E is -0.23.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.83M | 4.29M | 3.4M | 9.2M | 3.39M |
| Operating Income | -22.34M | -22.45M | -19.51M | -11.67M | -13.14M |
| Net Income | -21.4M | -20.96M | -18.98M | -11.16M | -12.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 22.42M | 83.38M | 92M | 14.92M |
| Operating Income | -108.49M | -21.08M | -8.55M | -25.91M | -88.73M |
| Net Income | -107.5M | -22.54M | -336k | -19.88M | -86.88M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 106.78M | 89.55M | 73.8M | 59.34M | 42.06M |
| Total Liabilities | 60.49M | 63.02M | 62.9M | 58.98M | 53.18M |
| Total Equity | 46.3M | 26.53M | 10.9M | 360k | -11.13M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 114.37M | 122.82M | 240.75M | 189.17M | 89.55M |
| Total Liabilities | 141.07M | 132.05M | 69.04M | 30.98M | 63.02M |
| Total Equity | -26.7M | -9.23M | 171.71M | 158.19M | 26.53M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -65.08M | -81.18M | -22.43M | -38.55M | -51.57M |
| Investing | 61.97M | 72.41M | -17k | -123k | -123k |
| Financing | 62.08M | 62.18M | 1.35M | 1.43M | 964k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -37.52M | -30.84M | -68.88M | 24.9M | -81.18M |
| Investing | -136k | -8k | -4k | -53.97M | 72.41M |
| Financing | 35.36M | 38.11M | 176.13M | 1,000 | 62.18M |
| Market Cap | 19.4M |
| Price to Earnings Ratio | -0.23 |
| Price to Sales Ratio | 1.34 |
| Price to Cash Ratio | 0.26 |
| Price to Book Ratio | 0.76 |
| Dividend Yield | - |
| Shares Outstanding | 41.75M |
| Average Volume (1 week) | 142.38k |
| Average Volume (1 Month) | 237.07k |
| 52 Week Change | -80.56% |
| 52 Week High | 2.77 |
| 52 Week Low | 0.38 |
| Spread (Intraday) | 0.04 (7.76%) |
| Company Name | Carisma Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.carismatx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
